The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present).

IF 5.4 2区 医学 Q1 CHEMISTRY, MEDICINAL Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI:10.1080/13543776.2024.2376632
Chen Zhang, Zhao-Hang Xue, Wei-Hao Luo, Mei-Yan Jiang, Yinuo Wu
{"title":"The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present).","authors":"Chen Zhang, Zhao-Hang Xue, Wei-Hao Luo, Mei-Yan Jiang, Yinuo Wu","doi":"10.1080/13543776.2024.2376632","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Phosphodiesterase 9 (PDE9) has been demonstrated as a potential target for neurological disorders and cardiovascular diseases, such as Alzheimer's disease and heart failure. For the last few years, a series of PDE9 inhibitors with structural diversities have been developed and patented by researchers and pharmaceutical companies, providing insights into first-in-class therapies of PDE9 drug candidates.</p><p><strong>Area covered: </strong>This review provides an overview of PDE9 inhibitors in patents from 2018 to the present.</p><p><strong>Expert opinion: </strong>Only a few of the current PDE9 inhibitors are highly selective over other PDEs, which limits their application in pharmacological and clinical research. The design and development of highly selective PDE9 inhibitors remain the top priority in future research. The advantages of targeting PDE9 rather than other PDEs in treating neurodegenerative diseases need to be explained thoroughly. Besides, application of PDE9 inhibitor-based combination therapies sheds light on treating diabetes and refractory heart diseases. Finally, PDE9 inhibitors should be further explored in clinical indications beyond neurological disorders and cardiovascular diseases.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"759-772"},"PeriodicalIF":5.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2024.2376632","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Phosphodiesterase 9 (PDE9) has been demonstrated as a potential target for neurological disorders and cardiovascular diseases, such as Alzheimer's disease and heart failure. For the last few years, a series of PDE9 inhibitors with structural diversities have been developed and patented by researchers and pharmaceutical companies, providing insights into first-in-class therapies of PDE9 drug candidates.

Area covered: This review provides an overview of PDE9 inhibitors in patents from 2018 to the present.

Expert opinion: Only a few of the current PDE9 inhibitors are highly selective over other PDEs, which limits their application in pharmacological and clinical research. The design and development of highly selective PDE9 inhibitors remain the top priority in future research. The advantages of targeting PDE9 rather than other PDEs in treating neurodegenerative diseases need to be explained thoroughly. Besides, application of PDE9 inhibitor-based combination therapies sheds light on treating diabetes and refractory heart diseases. Finally, PDE9 inhibitors should be further explored in clinical indications beyond neurological disorders and cardiovascular diseases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
磷酸二酯酶 9(PDE9)抑制剂的治疗潜力:专利综述(2018 年至今)。
简介磷酸二酯酶9(PDE9)已被证明是神经系统疾病和心血管疾病(如阿尔茨海默病和心力衰竭)的潜在靶点。过去几年中,研究人员和制药公司开发了一系列结构多样化的 PDE9 抑制剂并申请了专利,为 PDE9 候选药物的一流疗法提供了启示:本综述概述了2018年至今的专利中的PDE9抑制剂.专家观点:本综述概述了2018年至今的专利中的PDE9抑制剂:目前的PDE9抑制剂中只有少数对其他PDE具有高选择性,这限制了它们在药理学和临床研究中的应用。设计和开发高选择性的PDE9抑制剂仍是未来研究的重中之重。在治疗神经退行性疾病方面,靶向 PDE9 而非其他 PDEs 的优势需要得到深入解释。此外,基于 PDE9 抑制剂的联合疗法在治疗糖尿病和难治性心脏病方面的应用也会带来启示。最后,除了神经系统疾病和心血管疾病之外,PDE9 抑制剂在临床适应症方面的应用也有待进一步探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
12.10
自引率
1.50%
发文量
50
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
期刊最新文献
Expert opinion on therapeutic patents - manuscript ID EOTP-2024-ST-0024 has been submitted online. Mycobacterium tuberculosis inhibitors: an updated patent review (2021-present). Urease inhibitors for the treatment of H. pylori. A patent review of UNC-51-like kinase 1/2 inhibitors (2019-present). Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1